Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.)
As previously announced, the Company was notified by Nasdaq on February 13, 2025, that the Company's common shares failed to maintain a minimum bid price of US$1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. According to the Compliance Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company's common shares has been at or above $1.00 per share for 10 consecutive business days, from July 8, 2025, through July 21, 2025, and the matter is now closed.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Qualcomm (QCOM) Q2 Earnings Preview: What to Expect From Upcoming Report
July 29- Qualcomm (NASDAQ:QCOM) will reveal Q3 FY2025 results on July 30 after the market close. Wall Street expects adjusted EPS of $2.71, a 16.3% rise from a year ago, and revenue of $10.34 billion, up 10.1%. Investors eye the report amid worries that Apple (NASDAQ:AAPL) will shift to in?house modem chips next year, potentially trimming Qualcomm's handset chip sales. Smartphone market pressures and tariff risks in China also weigh on sentiment. Warning! GuruFocus has detected 6 Warning Signs with QCOM. Still, analysts note Qualcomm's growing footprint in IoT, automotive and edge AI. Bernstein's Stacy Rasgon keeps a Buy rating with a $185 target, calling Qualcomm heavily out of favor yet undervalued given its diverse product lineup and expected double?digit earnings growth. He says it's worth keeping on investors' radar. KeyBanc envisions wider semiconductor power with the help of demand in A as well as new product ramps. It predicts positive prospects of Qualcomm in Q3 but warns that second part of 2025 can have backdrafts due to Apple moving to other modems and sluggish Android market in China. The results will help to understand what degree of offset of challenges related to the handset is possible to be achieved by the divisions, which are engaged with non-smartphone, and whether Qualcomm will be able to quality its growth trend up to the end of the year. Based on the one year price targets offered by 30 analysts, the average target price for Qualcomm Inc is $177.50 with a high estimate of $225.00 and a low estimate of $140.00. The average target implies a upside of +10.21% from the current price of $161.05. Based on GuruFocus estimates, the estimated GF Value for Qualcomm Inc in one year is $160.62, suggesting a downside of -0.27% from the current price of $161.05. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus.
Yahoo
16 minutes ago
- Yahoo
Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board
We recently published . Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to close at $2.42 apiece and bucking the decline in the overall healthcare sector, as investors continued to load up positions following the addition of two CEOs in its board. Early last week, Vor Biopharma Inc. (NASDAQ:VOR) announced the addition of Alexander Cumbo and Michel Detheux to its board of directors, sparking confidence among investors amid ongoing efforts to strengthen leadership and strategic direction. Cumbo currently serves as president and CEO of Solid Biosciences. He was also the founding CEO of AavantiBio and brings more than 30 years of commercial and executive leadership, including nearly eight years at Sarepta Therapeutics, where he most recently served as Executive Vice President and Chief Commercial Officer. Meanwhile, Detheux is the president and CEO of iTeos Therapeutics. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company's lead anti-TIGIT antibody. Copyright: nimon / 123RF Stock Photo In a statement, Vor Biopharma Inc. (NASDAQ:VOR) said that Cumbo and Detheux's addition is invaluable as the company advances telitacicept through late-stage development and expands its long-term vision to bring transformative therapies to patients with autoimmune disease. While we acknowledge the potential of VOR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Super Micro (SMCI) Rallies 10.2% as US Freezes Export Curbs to China
We recently published . Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the best-performing stocks on Monday. Super Micro jumped for a fourth straight day on Monday, adding 10.24 percent to close at $60.05 apiece as investors cheered President Donald Trump's decision to freeze export restrictions on technology products to China as Washington and Beijing resume trade negotiations. The US and China will meet in Stockholm for a third round of trade talks on Monday, following previous meetings in Geneva and London. Known for its AI-focused server systems, Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the companies benefiting from increased technology spending this year. Year-to-date, its stock has gone up by almost 100 percent as more companies globally build large artificial intelligence workloads. Copyright: wavebreakmediamicro / 123RF Stock Photo In other developments, Super Micro Computer, Inc. (NASDAQ:SMCI) is set to announce the results of its earnings performance for the fourth quarter of fiscal year 2025 after market close on August 5. An investor call will be held on the same day to elaborate on the results. While we acknowledge the potential of SMCI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
